Clinical Trials Logo
  1. Home
  2. Congenital Chylothorax
  3. NCT00267345
  4. Details
NCT00267345 Clinical Trial

Measurement of Hormonal Concentration in Chylothorax Fluid in Infants With Congenital Chylothorax

Congenital Chylothorax Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT00267345
Other study ID # SHEBA-05-3927-JK-CTIL
Secondary ID
Status Recruiting
Phase N/A
First received December 19, 2005
Last updated February 28, 2007
Start date March 2005
Est. completion date October 2007

Study information
Verified date January 2006
Source Sheba Medical Center
Contact Jacob Kuint, MD
Phone 972-3-5302227
Email kuint-j@sheba.health.gov.il
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Observational

Clinical Trial Summary

Late onset Hypothyroidism was found in infant with congenital hypothyroidism. The hypothesis is that infants with congenital hypothyroidism may lose thyroxin and other hormones via the chylothorax fluid causing transient hypothyroidism. In this study hormonal concentration will be measured in the chyle as well as hormonal serum level.

Description:

Late onset Hypothyroidism was found in infant with congenital hypothyroidism. The hypothesis is that infants with congenital hypothyroidism may lose thyroxin and other hormones via the chylothorax fluid causing transient hypothyroidism. In this study hormonal concentration will be measured in the chyle as well as hormonal serum level.

Recruitment information / eligibility
Status Recruiting
Enrollment 15
Est. completion date October 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A to 10 Weeks
Eligibility Inclusion Criteria:

- Infants with congenital chylothorax requiring thorax drain

Exclusion Criteria:

Study Design

Observational Model: Case Control, Time Perspective: Longitudinal

Related Conditions & MeSH terms

Locations
Country Name City State
Israel Sheba Medical Center Ramat-Gan

Sponsors (1)
Lead Sponsor Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel,